biotech
<a href="https://www.fiercebiotech.com/biotech/bms-inks-15b-biobuck-deal-bag-hengrui-assets-tap-chinas-rd-speed" hreflang="en">Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed</a>
FierceBiotech
May 12, 2026 · 25s listen
Listen · FierceBiotech
<a href="https://www.fiercebiotech.com/biotech/bms-inks-15b-biobuck-deal-bag-hengrui-assets-tap-chinas-rd-speed" hreflang="en">Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed</a>
0:00-0:25
Live · Kokoro-82M
Audio pre-rendered by Storyflo · cached + delivered from the edge
Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be worth up to $15.2 billion.
Share
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to FierceBiotech.
Tip the publisher
70% goes to the publisher · 20% to whoever forwarded this to you · 10% keeps Storyflo running. Pay with USDC (instant, on-chain) or card (Stripe — Card, Link, Cash App, Apple Pay, Crypto, more).
or
Card path uses Stripe Checkout. USDC path settles on Base — gas-free for you.
Discussion
1500 characters left
Loading comments...